ASYMCHEM (06821) stock surged 5.04% in intraday trading, joining a broader rally in Contract Research Organization (CRO) stocks in the Hong Kong market. The surge comes amid positive sentiment surrounding the biomedical and pharmaceutical outsourcing sectors, driven by improving industry metrics and favorable market conditions.

The CRO sector is experiencing significant gains, with industry leaders showing strong performance. WUXI APPTEC rose 6.3%, WUXI BIO gained 6.02%, and PHARMARON climbed 4.11%. This sector-wide rally is supported by robust financial results from CXO companies, which reported year-over-year growth in revenue, net profit, and adjusted net profit for the first half of 2025, with further improvements seen in Q2 2025.

Analysts attribute the positive momentum to several factors, including expectations of US dollar rate cuts, increased domestic investment in innovative drugs, and a rise in biomedical IPOs on the STAR Market and Hong Kong Stock Exchange. The recovering biomedical investment sentiment, coupled with national policies encouraging innovation, is creating a favorable environment for companies in the pharmaceutical outsourcing services sector. Investors are advised to focus on firms specializing in ADC CDMO and weight-loss drug industrial chain peptide CDMO segments, as the industry moves towards stabilization and recovery despite ongoing challenges such as medical insurance cost controls.